


Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control *in vivo*

Monique Kauke, Nikki Ross, Dalia Burzyn, Shelly Martin, Ke Xu, Nuruddeen Lewis, Charan Leng, Su Chul Jang, Christine McCoy, Stephanie Yu, Kevin Dooley, Sriram Sathyanarayanan, Jonathan Finn


Codiak BioSciences, Cambridge, MA




Exosomes: nature's highly evolved messaging system




Engineered exosomes stably associate with target proteins




Targeted anti-Clec9a exosomes activate the STING pathway and induce pro-inflammatory cytokine production *in vitro*




PTGFRN identified as highly expressed, exosome-specific protein




Targeted exosomes alter cellular tropism *in vitro*




Targeted anti-Clec9a exosomes control CT26 tumor growth and induce anti-tumor immune responses




PTGFRN enables high-density exosome surface display of targeting domains



Targeted exosomes alter cellular tropism *in vivo*



Exosomes engineered to target cells for pharmacologic payload delivery



Presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting • November 9-14, 2020 • SITC 35th Anniversary Annual Meeting
All inquiries can be directed to the presenting author or by visiting www.codiakbio.com.

